Tenofovir in the treatment of hepatitis B virus infection after liver transplantation, a single center large population study

Fardad Ejtehadi; Mohammad Reza Pashaei; Alireza Shamsaeefar; Nasrin Motazedian; Gholam Reza Sivandzadeh; Ramin Niknam; Seyed Ali Malekhosseini; Kamran B Lankarni

Tenofovir in the treatment of hepatitis B virus infection after liver transplantation, a single center large population study

Gastroenterol Hepatol Bed Bench. 2021 Spring;14(2):154-159.

Authors

Fardad Ejtehadi¹, Mohammad Reza Pashaei², Alireza Shamsaeefar³, Nasrin Motazedian⁴, Gholam Reza Sivandzadeh¹, Ramin Niknam¹, Seyed Ali Malekhosseini³, Kamran B Lankarni⁵

Affiliations

¹ Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
² Department of Gastroenterology, Urmia University of Medical Sciences, Urmia, Iran.
³ Shiraz Organ Transplant Center, Shiraz University of Medical Sciences, Shiraz, Iran.
⁴ Shiraz Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
⁵ Health Policy Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran.

PMID: 33968342
PMCID: PMC8101521

Abstract

Aim: This study investigated the safety and efficacy of tenofovir disoproxil fumarate (TDF) compared with lamivudine (LAM) in the prevention of recurrent HBV infection after liver transplantation (LT).

Background: Although the recurrence of hepatitis B virus after liver transplantation (LT) is now very uncommon with both nucleoside and nucleotide analogs represented with lamivudine and tenofovir disoproxil fumarate, respectively, few studies have compared the two classes.

Methods: A total of 302 HBV-related post-transplant patients who received liver transplants from deceased donors were enrolled in this retrospective study from 2011 to 2015 in the Shiraz Organ Transplant Center, Iran. The demographic data, kidney function, recurrence, resistance rate, and acute rejections at 1-, 6-, and 12-month intervals and after 12 months were compared on TDF (n=209) and lamivudine (n=93) groups.

Results: During a median follow-up period of 42.9 months, mean creatinine level was not significantly different between the two groups. Hepatitis B virus recurrence rate as well as acute graft rejection episode had no statistical difference in either group over the study period.

Conclusion: Kidney function, creatinine level, disease recurrence, and acute graft rejection were comparable between tenofovir disoproxil fumarate and lamivudine in patients who received follow-up periods.

Keywords: Hepatitis B; Liver transplantation; Therapeutics.